REVIEW

De novo autoimmune hepatitis in liver transplant: State-of-the-art review

Ranka Vukotic, Giovanni Vitale, Antonia D'Errico-Grigioni, Luigi Muratori, Pietro Andreone

Ranka Vukotic, Giovanni Vitale, Luigi Muratori, Pietro Andreone, Dipartimento di Scienze Mediche e Chirurgiche, Università di Bologna, Policlinico Sant'Orsola-Malpighi, 40138 Bologna, Italy

Antonia D'Errico-Grigioni, Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, "F. Addarii" Institute of Oncology and Transplantation Pathology, Policlinico Sant'Orsola-Malpighi, 40138 Bologna, Italy

Author contributions: Vukotic R performed the search and review of the literature data and drafted the manuscript; Vitale G contributed to the search and review of the literature and revised the draft; D'Errico-Grigioni A provided histological specimens images, their interpretation and description; Muratori L contributed to the expert review of the literature data and critically analyzed the manuscript for its scientific content; Andreone P contributed to the review and interpretation of the literature, revised the draft for its intellectual and scientific content and is the guarantor of this review article; all authors approved the final version of the manuscript.

Conflict-of-interest statement: The Authors have no conflicts of interest to declare with concerns to this manuscript.

Correspondence to: Pietro Andreone, MD, Professor of Internal Medicine, Dipartimento di Scienze Mediche e Chirurgiche, Università di Bologna, Policlinico Sant'Orsola-Malpighi, Via Massarenti, 9, 40138 Bologna, Italy. pietro.andreone@unibo.it
Telephone: +39-51-2143618
Fax: +39-51-345806

Abstract

In the two past decades, a number of communications, case-control studies, and retrospective reports have appeared in the literature with concerns about the development of a complex set of clinical, laboratory and histological characteristics of a liver graft dysfunction that is compatible with autoimmune hepatitis. The *de novo* prefix was added to distinguish this entity from a pre-transplant primary autoimmune hepatitis, but the globally accepted criteria for the diagnosis of autoimmune hepatitis have been adopted in the diagnostic algorithm. Indeed, *de novo* autoimmune hepatitis is characterized by the typical liver necro-inflammation that is rich in plasma cells, the presence of interface hepatitis and the consequent laboratory findings of elevations in liver enzymes, increases in serum gamma globulin and the appearance of non-organ specific auto-antibodies. Still, the overall features of *de novo* autoimmune hepatitis appear not to be attributable to a univocal patho-physiological pathway because they can develop in the patients who have undergone liver transplantation due to different etiologies. Specifically, in subjects with hepatitis C virus recurrence, an interferon-containing antiviral treatment has been indicated as a potential inception of immune system derangement. Herein, we attempt to review the currently available knowledge about *de novo* liver autoimmunity and its clinical management.

Key words: *De novo* autoimmune hepatitis; Plasma-cell hepatitis; Liver transplant; Hepatitis C virus recurrence; Antiviral therapy; Autoimmunity; Differential diagnosis

© **The Author(s) 2016.** Published by Baishideng Publishing

Core tip: A post-transplant pathological entity that is characterized by liver enzyme peaks, circulating auto- and alloantibodies and histological findings of interface hepatitis and plasma-cell infiltrates has been described and is considered to be a diagnostic challenge. Although the optimization of the immunosuppressive regimen should be an efficacious tool for both its prevention and treatment, rescue onsets can occur with scenarios that threaten the graft and the patient's life. Hepatitis C recurrence is not the only pathogenic context of its occurrence in liver transplants, thus the clinical interest in this condition remains high.

INTRODUCTION

Liver transplantation (LT) represents the rescue therapy for end-stage liver disease (ESLD). The management of LT recipients is a complex issue because the natural history of the long-term survivors has been observed to depend on the possible development of unpredictable clinical complications such as acute and chronic rejection, *de novo* autoimmunity, and fibrosing cholestatic hepatitis[1-3]. For nearly two decades, the literature has provided information about series of LT patients, including children and adults, who develop transaminases increases, histological features of plasma-cell infiltrate and typical autoimmune liver serology. This phenomenon has been observed to be particularly challenging when it occurs during treatment with interferon for hepatitis C virus (HCV) recurrence[4]. While the recurrence of genuine autoimmune hepatitis (AIH) after LT should be dreaded in the mid-long-term[5-8], true *de novo* AIH can develop unpredictably in any period following LT, particularly in the setting of HCV recurrence. The hypotheses regarding the pathogenic pathways are not conclusive, and the examined risk factors have primarily focused on immunosuppression reductions or withdrawals, predisposing graft and/or host haplotypes and the use of immunomodulating agents. A prompt diagnosis and appropriate treatment of *de novo* AIH can prevent disease progression and graft loss.

COMMON DEFINITIONS AND CURRENT KNOWLEDGE

Autoimmune-based liver graft injury typically characterized by features of AIH, but occurring in transplant recipients for ESLD not caused by a previous autoimmune liver disease, has been described over the years in pediatric and adult LT. Likely because of its incomplete understanding, this disease has not yet been given a universally accepted denomination. The most common name of this condition, *i.e.*, *de novo* autoimmune hepatitis, was first used in 1998[9] (herein, "*de novo*" followed by the acronym AIH will be used), but has also been called post-LT AIH-like hepatitis[10], graft dysfunction mimicking AIH[11], posttransplant immune hepatitis[12], plasma-cell hepatitis[4,13], and *de novo* immune hepatitis[14]. The earliest descriptions of *de novo* AIH were reported in 1998 in pediatric patients and in 1999 in adult LT recipients who presented laboratory, autoimmune and histological features consistent with classic AIH[9,15]. A series of subsequent reports and studies increased the awareness of this disease in both children[12,16-30] and adults[4,11,13,14,31-53]. The experiences published thus far appear to be very heterogeneous in terms of methodology, patient identification and population size.

The earliest description of autoimmunity-related graft dysfunction in children[9] concerned 7/180 children who were observed for at least 5 years after LT. All seven of the patients presented histological features that were suggestive of *de novo* AIH: hypergammag-lobulinemia, high titers of antinuclear antibodies (ANA), and/or smooth muscle antibodies (SMA) and/or liver kidney microsomal (LKM) or even "atypical" LKM (only kidney stained) autoantibodies, and 6/7 exhibited satisfactory responses to steroids and azathioprine[9]. In this cohort, 5/7 patients had donor-HLA-DRB1*03:01 and/or HLA-DRB1*04:01 allele for human leukocyte antigen (HLA)[9], but the frequency was similar to the control group. Shortly after this description, a particularly severe course of *de novo* AIH in a pediatric population was described by Gupta *et al*[18] in 2001. These authors reported on 6/115 LT recipients with at least 5 years of post-LT observation who developed *de novo* AIH. The diagnosis was definitively confirmed by International Autoimmune Hepatitis Group (IAHG)[54,55] score in only one child, and the results from the other children indicated probable *de novo* AIH[18]. Regardless, severe progression to bridging fibrosis occurred in 80% of the patients, and graft loss occurred in 33% despite steroid and azathioprine treatment[18]. In the past decades, the monitoring of graft dysfunction with possible autoimmune etiology was globally sensitized for adult LT recipients. Particular focus was put on patients with HCV recurrence who developed *de novo* AIH features during or following an interferon-based antiviral treatment course. At our hospital, 9/44 LT patients who were treated from 2001 to 2004 with pegylated interferon (Peg-IFN) and ribavirin (RBV) for HCV recurrence experienced graft dysfunction compatible with *de novo* AIH[32]. Despite prompt treatment, 2/9 of these patients died, one had graft failure, and one required re-LT. Among the 5 patients

for whom remission was obtained, 3 experienced HCV-RNA relapse. In this series, no association was observed between the HLA type and the development of *de novo* AIH. In contrast, the administration of granulocyte colony-stimulating factor (GCSF) for the treatment of neutropenia appeared to be a protective factor while the use of anti-lymphocyte antibodies was significantly correlated with the development of *de novo* AIH in this cohort[32]. Fiel *et al*[4] reported series of 214 biopsies from 38 LT recipients between 1994 and 2006 that met the criteria for plasma-cell hepatitis. A high rate (55%) of acute graft rejection was reported in this population. The patients received one of the following treatments either alone or in combination: azathioprine, 6-mercaptopurine, prednisone, methyl-prednisolone, mycophenolate mofetil (MMF), and increased doses of a calcineurin inhibitor. Satisfactory outcomes were observed in 40% of the patients, and among the remaining patients, 10 died, 3 underwent re-LT, and 10 developed disease progression to cirrhosis[4]. More recently, cases of plasma-cell hepatitis during or after triple antiviral therapy with Peg-IFN, RBV and telaprevir have been described. Ikegami *et al*[38] reported 3 cases of plasma-cell hepatitis development during Peg-IFN and RBV treatment, shortly after the completion of triple regimen with telaprevir. Because significant drug-drug interactions are known to occur between calcineurin inhibitors and telaprevir, the patients received reduced doses of cyclosporine during telaprevir co-administration and were closely monitored for cyclosporine levels[38]. Following the onset of plasma-cell hepatitis, all cases were rescued with immunosuppressive regimen optimization *via* steroid pulses, increased cyclosporine doses, and/or the addition of MMF. In one case, the antiviral treatment was stopped for safety issues[38].

PATHOGENESIS INSIGHTS

Although the pathogenesis of *de novo* AIH in LT has not yet been fully clarified, it is generally accepted that this entity shares similar *movens* mechanisms with classical AIH. The susceptible genetic milieu given by HLA DRB1*0301 and/or DRB1*0401 alleles has been implicated in AIH pathogensis while its role in *de novo* AIH is inconclusive. It is thought that the presentation of antigens, either by the recipient or donor-presenting cells, triggers the memory T cells of the host's immune system, which results in consequent self-directed immune reactions[8,56-58]. The auto-reactivity of the T cells is stimulated by a cause that is independent of chronic inflammatory *noxa* and possibly leads to the endogenous presentation of self-epitopes[59]. This phenomenon is known as "epitope spreading"[59-61]. The mechanisms that are thought to contribute to the genesis of liver graft autoimmunity are at least in part induced by immunosuppressive agents[8]. Calcineurin inhibitors may cause the impairment of T-reg cells

function[8] *via* the recognition of self-antigens of the type Ⅱ major histocompatibility complex (MHC) by the T cells in a manner similar to that observed in graft-*vs*-host disease, by inducing a reduction in the production of interleukin-2 which is normally required for the survival and the proliferation of T-reg cells[62]. Notably, interactions between immunosuppressors and the maturation of the T cells have been hypothesized to exert even greater influence on immature immunity *e.g.*, in child LT recipients[63].

Moreover, viral molecular mimicry is believed to be among the potential causes of *de novo* autoimmunity[59], particularly the one exhibited by ubiquitous viruses, such as cytomegalovirus, Epstein-Barr virus and parvovirus, which are often found to infect immunosuppressed subjects and have been confirmed to be involved in a series of LT developing autoimmune features[49,64].

With special regard to the recurrence of HCV, the possible mechanisms that characterize *de novo* AIH in this setting have recently been delineated[2]. Specifically, it is hypothesized that interferon-alpha (acting on specific interferon-stimulated genes and in the context of the up-regulation of class I MHC) stimulates the activation of T-cells which, through the intensification of pro-inflammatory activity, enhance the presentation and release of antigens[2]. Apart from the virtuous effect on viral clearance, the recognition of viral antigens at the same time may lead to the expression of self-antigens, which can result in an alloimmune reaction sustained by memory T-cells[2,42,65].

HISTOLOGICAL FEATURES

In complex clinical settings in which different parameters (*e.g.*, the presence of autoantibodies without signs of effective liver injury) can mislead diagnosis, if a reasonable clinical suspicion emerges the liver biopsy should be performed. Thus far, the commonly observed histological characteristics of *de novo* AIH have been assimilated with those already described for classic AIH. Interface hepatitis and portal tract mononuclear infiltrate rich in plasma-cells are typical findings (Figure 1) along with accentuated lobular inflammation and necrosis, hepatocellular rosette (Figure 2) and features of centrolobular perivenulitis[1,66]. The interpretation of the liver histology is more complex for *de novo* AIH than for primary AIH because the former may be affected by conditions that resemble autoimmune liver injury and that by definition do not affect native livers, such as acute and chronic rejection[1]. A particularly abundant presence of plasma cells in the portal tract and an intense interface inflammation generally address the diagnosis but do not exempt from a careful differential appraisal[67,68]. Moreover, some intrinsic variables may influence the reading of liver allograft biopsy, such as the primary diagnosis that led to LT, the time from LT,

Figure 1 **The portal tract.** A: A moderate plasmacellular infiltrate. There is moderate interface hepatitis. The bile duct is regular. HE staining, 10 ×; B: A moderate chronic inflammatory infiltrate with plasma-cells. There is moderate interface hepatitis. The bile duct is regular. HE staining, 20 ×.

the immunosuppressive regimen, the center's previous experience in and awareness of the field, and the quality of information exchange between the clinician and pathologist[1,69].

CLINICAL ONSET AND DIFFERENTIAL DIAGNOSIS

The currently available data regarding the incidence of *de novo* AIH indicate rates of 5%-10% in pediatric LT recipients and 1%-2% in adult LT recipients, suggesting an infrequent post-LT complication in adults. Nonetheless, this disease should be considered when liver necrosis enzymes increase occurs in LT recipient, regardless of the post-LT epoch of development. Beginning with this laboratory finding, a differential algorithm is crucial for a correct diagnostic conclusion. Contextually, the elevation of gamma-globulin levels should be observed and graded, and the non-organ specific autoantibodies should be characterized[7,8] by an expert laboratory. In this sense, smooth-muscle antibodies positivity appears to be the most pathognomonic finding. With these concerns, the liver biopsy is performed and the histological features of *de novo* AIH should be observed to predominate over other etiologies of liver damage[66]. It is of note that in some cases, the diagnosis of *de novo* AIH arises from a standard one-year post-LT biopsy in the

Figure 2 **The lobule shows hepatocellular rosettas**. HE staining, 20 ×.

absence of prior major clinical or laboratory findings. Recently, an evaluation of the significance of non-organ specific autoantibodies was performed in a large transplanted population and revealed that the presence of serological autoimmunity seldom occurs in parallel with concrete clinical manifestations of autoimmune hepatitis[36]. This finding suggests, and it is indeed also our real-life experience, that liver biopsy is the most reliable diagnostic tool. The exclusion of possible distinct causes of graft dysfunction should comprise acute and chronic rejection, HCV recurrence focusing on its autoimmune-like presentation, biliary obstruction/stenosis, vascular complications, recurrent disease in recipients who received LT for primary biliary cirrhosis or primary sclerosing cholangitis and *ex novo* viral infections. Alternative biliary complications should be carefully excluded, particularly in patients who present with rapid laboratory deterioration including hyperbilirubinemia, which could reflect either a mechanical obstruction or the progression of underlying misrecognized *de novo* AIH to the deterioration of liver functionality. The application of the internationally agreed scoring systems for the diagnosis of AIH[54,70] to clinical, laboratory and histological parameters should definitely (or with high likelihood) confirm a suspected diagnosis of *de novo* AIH in subjects with consistent scores for whom the abovementioned alternative diseases can be excluded. However, in LT setting the immunosuppressive therapy could interfere with some of the parameters of the diagnostic criteria for the genuine AIH (*e.g.,* autoantibody profile). A complete response to the standard immunosuppressive regimen for AIH (*i.e.*, generous steroids doses in association with azathioprine) further supports the diagnosis. Notably, the steroids introduction for *de novo* AIH should be based on a meticulous diagnostic evaluation, particularly in patients with HCV recurrence, to prevent the exacerbation of viral replication[4].

The typical features that are common to each potential etiology of late graft dysfunction may be purposely reassumed to aid the differential diagnosis (Table 1). Nevertheless, despite apparently well-delineated diagnostic proceedings, a sharp distinction

Table 1 Differential features of de novo autoimmune hepatitis from other resembling etiologies of late graft dysfunction[1,2,7,8,58]

	de novo AIH	HCV recurrence	Acute rejection	Chronic rejection
Laboratory onset	HBV/HCV/HIV/CMV/EBV negative	HCV-RNA positive	Transaminases elevation	Transaminases normal/slightly increased
	Moderate liver enzymes increase	Low-moderate liver enzymes increase	Immunosuppressants levels under protective limits	Immunosuppressants levels under protective limits
	High IgG concentrations	ANA frequently positive	Autoantibodies negative or mild positive	Autoantibodies negative/mild positive
	Positivity for ANA, SMA, LKM, atypical LKM (anti-GSTT1), and/or AMA	SMA, AMA, LKM rarely positive		
Clinical presentation	Onset variable from indolent to overt, may follow an antiviral treatment for HCV recurrence, especially when viral clearance is obtained	Gradual progression to cirrhosis except severe forms	Rapidly progressive deterioration of liver function scores	Silent onset Slow progression to deterioration of liver function scores
	IAHG probable/definite diagnosis			
Histology	Portal tract infiltrate rich in plasma-cells	Chronic logistic infiltrate	Central perivenulitis	Biliary inflammatory and ischemic pattern: bile ductopenia and inflammation, artheriolar/capillary obliterative features or loss
	Interface hepatitis	Possible interface hepatitis	Hepatic venous endothelitis	
	Rosette	Confluent/bridging necrosis	Mononuclear/mixed portal infiltrate	
	Lobular inflammation ± bridging/confluent necrotic foci	Progression to cirrhosis	Bile ducts inflammation	
		Possible fibrosing cholestatic hepatitis		
Treatment	Prednis(ol)one ± MMF/azathioprine	Antiviral treatment	Steroids bolus	Steroids bolus
		Immunosuppression levels monitoring	Adjustment of immunosuppressive regimen	Switch to/addition of a new immunosuppressant and/or optimization of current regimen)

AIH: Autoimmune hepatitis; HBV: Hepatitis B virus; HCV: Hepatitis C virus; HIV: Human immunodeficiency virus; CMV: Cytomegalovirus; EBV: Epstein-Barr virus; ANA: Antinuclear antibody; SMA: Smooth muscle antibody; LKM: Liver kidney-microsomal antibody; GSTT1: Glutathione S-transferase T1; AMA: Anti-mitochondrial antibody; IAHG: International autoimmune hepatitis group; MMF: Mycophenolate mofetil.

of de novo autoimmunity, particularly from forms of graft rejection, continues to be frequently question of nuance[4,34,65,66,71].

RISK FACTORS, PREVENTION AND TREATMENT

The current knowledge of de novo AIH suggests that whether and when a patient who has undergone LT for autoimmunity-unrelated liver disease will develop de novo AIH are not predictable. The relatively recent increase in the awareness of this clinical entity has effectively resulted in numerous reports in literature, but their heterogeneity continues to preclude the identification of clear predictive and risk factors of de novo AIH. Nevertheless, some studies have been conducted with this purpose. A large case-control study was conducted in the United States by Venick et al[17] with data from 788 grafts received by 619 children in a single center during an approximately twenty-year period. Among patients, 41 children who developed a de novo AIH (6.6%) were successively compared with control subjects who were matched in terms of the year of LT, age at LT and initial diagnosis[17]. None among the variables that were compared (age, gender, race, initial diagnosis, ischemia time, graft type, Epstein-Barr virus and cytomegalovirus infections, HLA haplotype and immunosuppressive regimen)

was found to be different between the two groups[17]. In contrast, the authors found that the number of patients in mono-immunosuppression, the number of patients to whom steroids were discontinued and the number of those who presented an allograft rejection were all higher in the group of de novo AIH[17]. Notably, in nearly all of the patients, prednisone with or without MMF was found to be a successful treatment choice[17].

In 2008[33], a study examined the potential role in the pathogenesis of de novo AIH of immunoglobulin subtype 4 (IgG4), which has been implicated in different autoimmune diseases[72]. Four of 72 (5.6%) adult living donor LT recipients who underwent transplantation within a 10-year period at a single center were diagnosed with de novo AIH[33]. The serum and liver tissue levels of IgG4 of these patients were adequately measured and found to be normal with the exception of one patient who exhibited only a mild positivity and thus suggesting that IgG4 is not a plausible co-factor in the development of de novo AIH[33].

Lodato et al[73] compared LT recipients treated with GCSF to those who did not receive GCSF in terms of the incidence of de novo AIH. A significantly lower incidence was observed in the GCSF group, which supports the protective immunomodulatory effect of GCSF against liver autoimmunity in the post-LT setting[73].

Several studies[14,74-76] were conducted that focused on the role of the glutathione S-transferase T1 (GSTT1) gene as a risk factor for *de novo* AIH development. Aguilera *et al*[77] identified in patients who present with *de novo* AIH, specific antibodies produced against donor GSTT1 gene due to a mismatch between the wild-type carried by the donor and recipient's null genotype. Moreover, a retrospective analysis of liver biopsies from patients with *de novo* AIH who expressed GSTT1-Ab was conducted by the same authors to explore the presence of complement component 4d (C4d)[77]. C4d-positivity was observed to localize in the portal tracts of nearly all of the *de novo* AIH specimens, while in two control groups, sinusoidal C4d-positive pattern was present in 4/7 biopsies from patients who experienced rejection[77]. Finally, this question was further explored in successive studies that identified the influence of the type of immunosuppression on the definite clinical manifestations of GSTT1 genetic mismatch[78]. In the latter data, among 35 LT recipients a significantly greater proportion of those who did not produce anti-GSTT1 antibodies and did not manifest *de novo* AIH was observed among the patients who received tacrolimus (± MMF) than among those who received cyclosporine[78]. In a study of a GSTT1-mismatch positive LT population, the male gender of the donor and non-alcohol related pre-LT disease were found to be predictive of *de novo* AIH[79].

In another study[80] an enhanced immunosuppressive regimen that included steroids in addition to tacrolimus and MMF, has been shown to be protective against late graft rejection. In turn, as reported in the above-mentioned studies, the occurrence of rejection was implied to be a predisposing factor for the appearance of *de novo* AIH[17]. Indeed, a study of a large series of adult LT recipients with features compatible with acute rejection observed that more than half of the patients were effectively diagnosed with *de novo* AIH[4].

Finally, it is worth noting that in LT recipients for HCV-related end-stage liver disease, HCV *per se* can be associated with serum autoimmunity profile positivity and the systemic manifestations of this condition[81,82]. Indeed, HCV infection is thought to incite autoimmune injury in genetically predisposed subjects[83].

Corticosteroids remain the milestone of the treatment of *de novo* AIH but should be accompanied by the optimization of calcineurin inhibitors posology[84]. Azathioprine or MMF should be added, whereas calcineurin inhibitors and steroids do not provide prompt benefit[84].

CONCLUSION

De novo autoimmunity in LT is a complex clinico-pathological issue due to both the incomplete understanding of its pathogenesis and its challenging diagnostic interpretation. Fortunately, growing experience and sensitivity to this post-LT complication have been elicited by numerous reports in the literature,

in-depth pathophysiological studies and the sharing of real-life experiences of therapeutic approaches. Steroids seem to be successful in most cases, but there is no universally accepted therapeutic scheme, and the most adequate treatment needs to be tailored according to each patient's clinical history and situation.

In the near future antiviral treatments for post-LT HCV recurrence will hopefully be fully based on potent new direct-acting antiviral agents in all-oral, interferon-free regimens. However, *de novo* AIH has been widely observed to develop in LT recipients with etiologies other than HCV. Therefore, given the complexity of the follow-up of liver allografts, strict awareness is needed in this setting for the detection and correct interpretation of liver enzymes increase, particularly during but not limited to long-term post-LT follow-up.

REFERENCES

1   **Hübscher SG**. What is the long-term outcome of the liver allograft? *J Hepatol* 2011; **55**: 702-717 [PMID: 21426919 DOI: 10.1016/j.jhep.2011.03.005]

2   **Selzner N**, Guindi M, Renner EL, Berenguer M. Immune-mediated complications of the graft in interferon-treated hepatitis C positive liver transplant recipients. *J Hepatol* 2011; **55**: 207-217 [PMID: 21145865 DOI: 10.1016/j.jhep.2010.11.012]

3   **Lucey MR**, Terrault N, Ojo L, Hay JE, Neuberger J, Blumberg E, Teperman LW. Long-term management of the successful adult liver transplant: 2012 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. *Liver Transpl* 2013; **19**: 3-26 [PMID: 23281277 DOI: 10.1002/lt.23566]

4   **Fiel MI**, Agarwal K, Stanca C, Elhajj N, Kontorinis N, Thung SN, Schiano TD. Posttransplant plasma cell hepatitis (de novo autoimmune hepatitis) is a variant of rejection and may lead to a negative outcome in patients with hepatitis C virus. *Liver Transpl* 2008; **14**: 861-871 [PMID: 18508382 DOI: 10.1002/lt.21447]

5   **Gautam M**, Cheruvattath R, Balan V. Recurrence of autoimmune liver disease after liver transplantation: a systematic review. *Liver Transpl* 2006; **12**: 1813-1824 [PMID: 17031826 DOI: 10.1002/lt.20910]

6   **Mendes F**, Couto CA, Levy C. Recurrent and de novo autoimmune liver diseases. *Clin Liver Dis* 2011; **15**: 859-878 [PMID: 22032533 DOI: 10.1016/j.cld.2011.08.008]

7   **Czaja AJ**. Diagnosis, pathogenesis, and treatment of autoimmune hepatitis after liver transplantation. *Dig Dis Sci* 2012; **57**: 2248-2266 [PMID: 22562533 DOI: 10.1007/s10620-012-2179-3]

8   **Liberal R**, Longhi MS, Grant CR, Mieli-Vergani G, Vergani D. Autoimmune hepatitis after liver transplantation. *Clin Gastroenterol Hepatol* 2012; **10**: 346-353 [PMID: 22056300 DOI: 10.1016/j.cgh.2011.10.028]

9   **Kerkar N**, Hadzić N, Davies ET, Portmann B, Donaldson PT, Rela M, Heaton ND, Vergani D, Mieli-Vergani G. De-novo autoimmune hepatitis after liver transplantation. *Lancet* 1998; **351**: 409-413 [PMID: 9482295 DOI: 10.1016/S0140-6736(97)06478-7]

10   **Khettry U**, Huang WY, Simpson MA, Pomfret EA, Pomposelli JJ, Lewis WD, Jenkins RL, Gordon FD. Patterns of recurrent hepatitis C after liver transplantation in a recent cohort of patients. *Hum Pathol* 2007; **38**: 443-452 [PMID: 17188331 DOI: 10.1016/j.humpath.2006.08.028]

11   **Heneghan MA**, Portmann BC, Norris SM, Williams R, Muiesan P, Rela M, Heaton ND, O'Grady JG. Graft dysfunction mimicking autoimmune hepatitis following liver transplantation in adults. *Hepatology* 2001; **34**: 464-470 [PMID: 11526530 DOI: 10.1053/jhep.2001.26756]

12   **Andries S**, Casamayou L, Sempoux C, Burlet M, Reding R,

Bernard Otte J, Buts JP, Sokal E. Posttransplant immune hepatitis in pediatric liver transplant recipients: incidence and maintenance therapy with azathioprine. *Transplantation* 2001; **72**: 267-272 [PMID: 11477351]

13 **Ward SC**, Schiano TD, Thung SN, Fiel MI. Plasma cell hepatitis in hepatitis C virus patients post-liver transplantation: case-control study showing poor outcome and predictive features in the liver explant. *Liver Transpl* 2009; **15**: 1826-1833 [PMID: 19938116 DOI: 10.1002/lt.21949]

14 **Aguilera I**, Wichmann I, Sousa JM, Bernardos A, Franco E, García-Lozano JR, Núñez-Roldán A. Antibodies against glutathione S-transferase T1 (GSTT1) in patients with de novo immune hepatitis following liver transplantation. *Clin Exp Immunol* 2001; **126**: 535-539 [PMID: 11737073 DOI: 10.1046/j.1365-2249.2001.01682.x]

15 **Jones DE**, James OF, Portmann B, Burt AD, Williams R, Hudson M. Development of autoimmune hepatitis following liver transplantation for primary biliary cirrhosis. *Hepatology* 1999; **30**: 53-57 [PMID: 10385638 DOI: 10.1002/hep.510300103]

16 **Kerkar N**, Dugan C, Rumbo C, Morotti RA, Gondolesi G, Shneider BL, Emre S. Rapamycin successfully treats post-transplant autoimmune hepatitis. *Am J Transplant* 2005; **5**: 1085-1089 [PMID: 15816890 DOI: 10.1111/j.1600-6143.2005.00801.x]

17 **Venick RS**, McDiarmid SV, Farmer DG, Gornbein J, Martin MG, Vargas JH, Ament ME, Busuttil RW. Rejection and steroid dependence: unique risk factors in the development of pediatric posttransplant de novo autoimmune hepatitis. *Am J Transplant* 2007; **7**: 955-963 [PMID: 17391135 DOI: 10.1111/j.1600-6143.2006.01717.x]

18 **Gupta P**, Hart J, Millis JM, Cronin D, Brady L. De novo hepatitis with autoimmune antibodies and atypical histology: a rare cause of late graft dysfunction after pediatric liver transplantation. *Transplantation* 2001; **71**: 664-668 [PMID: 11292299]

19 **Hernandez HM**, Kovarik P, Whitington PF, Alonso EM. Autoimmune hepatitis as a late complication of liver transplantation. *J Pediatr Gastroenterol Nutr* 2001; **32**: 131-136 [PMID: 11321380]

20 **Tamaro G**, Sonzogni A, Torre G. Monitoring "de novo" autoimmune hepatitis (LKM positive) by serum type-IV collagen after liver transplant: a paediatric case. *Clin Chim Acta* 2001; **310**: 25-29 [PMID: 11485751 DOI: 10.1016/S0009-8981(01)00509-5]

21 **Gibelli NE**, Tannuri U, Mello ES, Cançado ER, Santos MM, Ayoub AA, Maksoud-Filho JG, Velhote MC, Silva MM, Pinho-Apezzato ML, Maksoud JG. Successful treatment of de novo autoimmune hepatitis and cirrhosis after pediatric liver transplantation. *Pediatr Transplant* 2006; **10**: 371-376 [PMID: 16677364 DOI: 10.1111/j.1399-3046.2005.00470.x]

22 **Evans HM**, Kelly DA, McKiernan PJ, Hübscher S. Progressive histological damage in liver allografts following pediatric liver transplantation. *Hepatology* 2006; **43**: 1109-1117 [PMID: 16628633 DOI: 10.1002/hep.21152]

23 **Herzog D**, Soglio DB, Fournet JC, Martin S, Marleau D, Alvarez F. Interface hepatitis is associated with a high incidence of late graft fibrosis in a group of tightly monitored pediatric orthotopic liver transplantation patients. *Liver Transpl* 2008; **14**: 946-955 [PMID: 18581476 DOI: 10.1002/lt.21444]

24 **Oya H**, Sato Y, Yamamoto S, Kobayashi T, Watanabe T, Kokai H, Hatakeyama K. De novo autoimmune hepatitis after living donor liver transplantation in a 25-day-old newborn baby: a case report. *Transplant Proc* 2009; **41**: 433-434 [PMID: 19249573 DOI: 10.1016/j.transproceed.2008.10.031]

25 **Spada M**, Bertani A, Sonzogni A, Petz W, Riva S, Torre G, Melzi ML, Alberti D, Colledan M, Segalin A, Lucianetti A, Gridelli B. A cause of late graft dysfunction after liver transplantation in children: de-novo autoimmune hepatitis. *Transplant Proc* 2001; **33**: 1747-1748 [PMID: 11267495 DOI: 10.1016/S0041-1345(00)02826-8]

26 **Petz W**, Sonzogni A, Bertani A, Spada M, Lucianetti A, Colledan M, Gridelli B. A cause of late graft dysfunction after pediatric liver transplantation: de novo autoimmune hepatitis. *Transplant Proc* 2002; **34**: 1958-1959 [PMID: 12176643 DOI: 10.1016/S0041-1345(02)03137-8]

27 **Riva S**, Sonzogni A, Bravi M, Bertani A, Alessio MG, Candusso M, Stroppa P, Melzi ML, Spada M, Gridelli B, Colledan M, Torre G. Late graft dysfunction and autoantibodies after liver transplantation in children: preliminary results of an Italian experience. *Liver Transpl* 2006; **12**: 573-577 [PMID: 16555335 DOI: 10.1002/lt.20673]

28 **Cho JM**, Kim KM, Oh SH, Lee YJ, Rhee KW, Yu E. De novo autoimmune hepatitis in Korean children after liver transplantation: a single institution's experience. *Transplant Proc* 2011; **43**: 2394-2396 [PMID: 21839275 DOI: 10.1016/j.transproceed.2011.05.030]

29 **Hadžić N**, Quaglia A, Cotoi C, Hussain MJ, Brown N, Vergani D, Mieli-Vergani G. Immunohistochemical phenotyping of the inflammatory infiltrate in de novo autoimmune hepatitis after liver transplantation in children. *Pediatr Transplant* 2012; **16**: 501-510 [PMID: 22672703 DOI: 10.1111/j.1399-3046.2012.01723.x]

30 **Wozniak LJ**, Hickey MJ, Venick RS, Vargas JH, Farmer DG, Busuttil RW, McDiarmid SV, Reed EF. Donor-specific HLA Antibodies Are Associated With Late Allograft Dysfunction After Pediatric Liver Transplantation. *Transplantation* 2015; **99**: 1416-1422 [PMID: 26038872 DOI: 10.1097/TP.0000000000000796]

31 **Keaveny AP**, Gordon FD, Khettry U. Post-liver transplantation de novo hepatitis with overlap features. *Pathol Int* 2005; **55**: 660-664 [PMID: 16185298 DOI: 10.1111/j.1440-1827.2005.01886.x]

32 **Berardi S**, Lodato F, Gramenzi A, D'Errico A, Lenzi M, Bontadini A, Morelli MC, Tamè MR, Piscaglia F, Biselli M, Sama C, Mazzella G, Pinna AD, Grazi G, Bernardi M, Andreone P. High incidence of allograft dysfunction in liver transplanted patients treated with pegylated-interferon alpha-2b and ribavirin for hepatitis C recurrence: possible de novo autoimmune hepatitis? *Gut* 2007; **56**: 237-242 [PMID: 16798778 DOI: 10.1136/gut.2006.092064]

33 **Eguchi S**, Takatsuki M, Hidaka M, Tajima Y, Zen Y, Nakanuma Y, Kanematsu T. De novo autoimmune hepatitis after living donor liver transplantation is unlikely to be related to immunoglobulin subtype 4-related immune disease. *J Gastroenterol Hepatol* 2008; **23**: e165-e169 [PMID: 18505414 DOI: 10.1111/j.1440-1746.2008.05347.x]

34 **Merli M**, Gentili F, Giusto M, Attili AF, Corradini SG, Mennini G, Rossi M, Corsi A, Bianco P. Immune-mediated liver dysfunction after antiviral treatment in liver transplanted patients with hepatitis C: allo or autoimmune de novo hepatitis? *Dig Liver Dis* 2009; **41**: 345-349 [PMID: 19162574 DOI: 10.1016/j.dld.2008.09.015]

35 **Zhao XY**, Rakhda MI, Wang TI, Jia JD. Immunoglobulin G4-associated de novo autoimmune hepatitis after liver transplantation for chronic hepatitis B- and C-related cirrhosis and hepatocellular carcinoma: a case report with literature review. *Transplant Proc* 2013; **45**: 824-827 [PMID: 23498828 DOI: 10.1016/j.transproceed.2012.02.049]

36 **Foschi A**, Zavaglia CA, Fanti D, Mazzarelli C, Perricone G, Vangeli M, Viganò R, Belli LS. Autoimmunity after liver transplantation: a frequent event but a rare clinical problem. *Clin Transplant* 2015; **29**: 161-166 [PMID: 25522890 DOI: 10.1111/ctr.12498]

37 **Castillo-Rama M**, Sebagh M, Sasatomi E, Randhawa P, Isse K, Salgarkar AD, Ruppert K, Humar A, Demetris AJ. "Plasma cell hepatitis" in liver allografts: identification and characterization of an IgG4-rich cohort. *Am J Transplant* 2013; **13**: 2966-2977 [PMID: 24011021 DOI: 10.1111/ajt.12413]

38 **Ikegami T**, Yoshizumi T, Shirabe K, Maehara Y. Frequent plasma cell hepatitis during telaprevir-based triple therapy for hepatitis C after liver transplantation. *J Hepatol* 2014; **60**: 894-896 [PMID: 24316026 DOI: 10.1016/j.jhep.2013.10.037]

39 **Rodríguez-Diaz Y**, Reyes-Rodriguez R, Dorta-Francisco MC, Aguilera I, Perera-Molinero A, Moneva-Arce E, Aviles-Ruiz JF. De novo autoimmune hepatitis following liver transplantation for primary biliary cirrhosis. *Transplant Proc* 2006; **38**: 1467-1470 [PMID: 16797335 DOI: 10.1016/j.transproceed.2006.03.071]

40 **Cholongitas E**, Samonakis D, Patch D, Senzolo M, Burroughs AK, Quaglia A, Dhillon A. Induction of autoimmune hepatitis by pegylated interferon in a liver transplant patient with recurrent

hepatitis C virus. *Transplantation* 2006; **81**: 488-490 [PMID: 16477242 DOI: 10.1097/01.tp.0000196716.07188.c4]

41   **Kontorinis N**, Agarwal K, Elhajj N, Fiel MI, Schiano TD. Pegylated interferon-induced immune-mediated hepatitis post-liver transplantation. *Liver Transpl* 2006; **12**: 827-830 [PMID: 16628699 DOI: 10.1002/lt.20706]

42   **Takeishi K**, Shirabe K, Toshima T, Ikegami T, Morita K, Fukuhara T, Motomura T, Mano Y, Uchiyama H, Soejima Y, Taketomi A, Maehara Y. De novo autoimmune hepatitis subsequent to switching from type 2b to type 2a alpha-pegylated interferon treatment for recurrent hepatitis C after liver transplantation: report of a case. *Surg Today* 2011; **41**: 1016-1019 [PMID: 21748625 DOI: 10.1007/s00595-010-4392-z]

43   **Levitsky J**, Fiel MI, Norvell JP, Wang E, Watt KD, Curry MP, Tewani S, McCashland TM, Hoteit MA, Shaked A, Saab S, Chi AC, Tien A, Schiano TD. Risk for immune-mediated graft dysfunction in liver transplant recipients with recurrent HCV infection treated with pegylated interferon. *Gastroenterology* 2012; **142**: 1132-1139.e1 [PMID: 22285805 DOI: 10.1053/j.gastro.2012.01.030]

44   **Salcedo M**, Vaquero J, Bañares R, Rodríguez-Mahou M, Alvarez E, Vicario JL, Hernández-Albújar A, Tíscar JL, Rincón D, Alonso S, De Diego A, Clemente G. Response to steroids in de novo autoimmune hepatitis after liver transplantation. *Hepatology* 2002; **35**: 349-356 [PMID: 11826408 DOI: 10.1053/jhep.2002.31167]

45   **Tan CK**, Sian Ho JM. Concurrent de novo autoimmune hepatitis and recurrence of primary biliary cirrhosis post-liver transplantation. *Liver Transpl* 2001; **7**: 461-465 [PMID: 11349269 DOI: 10.1053/jlts.2001.23792]

46   **Yoshizawa K**, Shirakawa H, Ichijo T, Umemura T, Tanaka E, Kiyosawa K, Imagawa E, Matsuda K, Hidaka E, Sano K, Nakazawa Y, Ikegami T, Hashikura Y, Miyagawa S, Ota M, Nakano M. De novo autoimmune hepatitis following living-donor liver transplantation for primary biliary cirrhosis. *Clin Transplant* 2008; **22**: 385-390 [PMID: 18190552 DOI: 10.1111/j.1399-0012.2007.00787.x]

47   **Inui A**, Sogo T, Komatsu H, Miyakawa H, Fujisawa T. Antibodies against cytokeratin 8/18 in a patient with de novo autoimmune hepatitis after living-donor liver transplantation. *Liver Transpl* 2005; **11**: 504-507 [PMID: 15838910 DOI: 10.1002/lt.20404]

48   **Zhang Y**, Wang B, Wang T. De novo autoimmune hepatitis with centrilobular necrosis following liver transplantation for primary biliary cirrhosis: a case report. *Transplant Proc* 2010; **42**: 3854-3857 [PMID: 21094869 DOI: 10.1016/j.transproceed.2010.08.062]

49   **Sakamoto T**, Sato Y, Yamamoto S, Oya H, Hatakeyama K. De novo ulcerative colitis and autoimmune hepatitis after living related liver transplantation from cytomegalovirus-positive donor to cytomegalovirus-negative recipient: a case report. *Transplant Proc* 2012; **44**: 570-573 [PMID: 22410071 DOI: 10.1016/j.transproceed.2012.01.007]

50   **Miyagawa-Hayashino A**, Haga H, Egawa H, Hayashino Y, Sakurai T, Minamiguchi S, Tanaka K, Manabe T. Outcome and risk factors of de novo autoimmune hepatitis in living-donor liver transplantation. *Transplantation* 2004; **78**: 128-135 [PMID: 15257051]

51   **Miyagawa-Hayashino A**, Haga H, Sakurai T, Shirase T, Manabe T, Egawa H. De novo autoimmune hepatitis affecting allograft but not the native liver in auxiliary partial orthotopic liver transplantation. *Transplantation* 2003; **76**: 271-272 [PMID: 12865828 DOI: 10.1097/01.TP.0000072338.88465.59]

52   **Casanovas T**, Argudo A, Peña-Cala MC. Effectiveness and safety of everolimus in the treatment of autoimmune hepatitis related to anti-hepatitis C virus therapy after liver transplant: three case reports. *Transplant Proc* 2011; **43**: 2233-2236 [PMID: 21839242 DOI: 10.1016/j.transproceed.2011.05.028]

53   **Sebagh M**, Castillo-Rama M, Azoulay D, Coilly A, Delvart V, Allard MA, Dos Santos A, Johanet C, Roque-Afonso AM, Saliba F, Duclos-Vallée JC, Samuel D, Demetris AJ. Histologic findings predictive of a diagnosis of de novo autoimmune hepatitis after liver transplantation in adults. *Transplantation* 2013; **96**: 670-678

[PMID: 23982338 DOI: 10.1097/TP.0b013e31829eda7f]

54   **Alvarez F**, Berg PA, Bianchi FB, Bianchi L, Burroughs AK, Cancado EL, Chapman RW, Cooksley WG, Czaja AJ, Desmet VJ, Donaldson PT, Eddleston AL, Fainboim L, Heathcote J, Homberg JC, Hoofnagle JH, Kakumu S, Krawitt EL, Mackay IR, MacSween RN, Maddrey WC, Manns MP, McFarlane IG, Meyer zum Büschenfelde KH, Zeniya M. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. *J Hepatol* 1999; **31**: 929-938 [PMID: 10580593 DOI: 10.1016/S0168-8278(99)80297-9]

55   **Johnson PJ**, McFarlane IG. Meeting report: International Autoimmune Hepatitis Group. *Hepatology* 1993; **18**: 998-1005 [PMID: 8406375]

56   **Guido M**, Burra P. De novo autoimmune hepatitis after liver transplantation. *Semin Liver Dis* 2011; **31**: 71-81 [PMID: 21344352 DOI: 10.1055/s-0031-1272834]

57   **Sanchez-Fueyo A**. Tolerance profiles and immunosuppression. *Liver Transpl* 2013; **19** Suppl 2: S44-S48 [PMID: 24108496 DOI: 10.1002/lt.23749]

58   **Mieli-Vergani G**, Vergani D. De novo autoimmune hepatitis after liver transplantation. *J Hepatol* 2004; **40**: 3-7 [PMID: 14672607 DOI: 10.1016/j.jhep.2003.10.022]

59   **Getts DR**, Chastain EM, Terry RL, Miller SD. Virus infection, antiviral immunity, and autoimmunity. *Immunol Rev* 2013; **255**: 197-209 [PMID: 23947356 DOI: 10.1111/imr.12091]

60   **Vanderlugt CJ**, Miller SD. Epitope spreading. *Curr Opin Immunol* 1996; **8**: 831-836 [PMID: 8994863 DOI: 10.1016/S0952-7915(96)80012-4]

61   **Vanderlugt CL**, Miller SD. Epitope spreading in immune-mediated diseases: implications for immunotherapy. *Nat Rev Immunol* 2002; **2**: 85-95 [PMID: 11910899 DOI: 10.1038/nri724]

62   **Kang HG**, Zhang D, Degauque N, Mariat C, Alexopoulos S, Zheng XX. Effects of cyclosporine on transplant tolerance: the role of IL-2. *Am J Transplant* 2007; **7**: 1907-1916 [PMID: 17617853 DOI: 10.1111/j.1600-6143.2007.01881.x]

63   **Schreuder TC**, Hübscher SG, Neuberger J. Autoimmune liver diseases and recurrence after orthotopic liver transplantation: what have we learned so far? *Transpl Int* 2009; **22**: 144-152 [PMID: 18662365 DOI: 10.1111/j.1432-2277.2008.00729.x]

64   **Varani S**, Muratori L, De Ruvo N, Vivarelli M, Lazzarotto T, Gabrielli L, Bianchi FB, Bellusci R, Landini MP. Autoantibody appearance in cytomegalovirus-infected liver transplant recipients: correlation with antigenemia. *J Med Virol* 2002; **66**: 56-62 [PMID: 11748659 DOI: 10.1002/jmv.2111]

65   **Fiel MI**, Schiano TD. Plasma cell hepatitis (de-novo autoimmune hepatitis) developing post liver transplantation. *Curr Opin Organ Transplant* 2012; **17**: 287-292 [PMID: 22498651 DOI: 10.1097/MOT.0b013e3283536622]

66   **Demetris AJ**, Adeyi O, Bellamy CO, Clouston A, Charlotte F, Czaja A, Daskal I, El-Monayeri MS, Fontes P, Fung J, Gridelli B, Guido M, Haga H, Hart J, Honsova E, Hubscher S, Itoh T, Jhala N, Jungmann P, Khettry U, Lassman C, Ligato S, Lunz JG, Marcos A, Minervini MI, Mölne J, Nalesnik M, Nasser I, Neil D, Ochoa E, Pappo O, Randhawa P, Reinholt FP, Ruiz P, Sebagh M, Spada M, Sonzogni A, Tsamandas AC, Wernerson A, Wu T, Yilmaz F. Liver biopsy interpretation for causes of late liver allograft dysfunction. *Hepatology* 2006; **44**: 489-501 [PMID: 16871565 DOI: 10.1002/hep.21280]

67   **Kallwitz ER**. Recurrent hepatitis C virus after transplant and the importance of plasma cells on biopsy. *World J Gastroenterol* 2013; **19**: 158-160 [PMID: 23345937 DOI: 10.3748/wjg.v19.i2.158]

68   **Carbone M**, Neuberger JM. Autoimmune liver disease, autoimmunity and liver transplantation. *J Hepatol* 2014; **60**: 210-223 [PMID: 24084655 DOI: 10.1016/j.jhep.2013.09.020]

69   **Pappo O**, Ramos H, Starzl TE, Fung JJ, Demetris AJ. Structural integrity and identification of causes of liver allograft dysfunction occurring more than 5 years after transplantation. *Am J Surg Pathol* 1995; **19**: 192-206 [PMID: 7832279]

70   **Vergani D**, Alvarez F, Bianchi FB, Cançado EL, Mackay IR, Manns MP, Nishioka M, Penner E. Liver autoimmune serology: a

consensus statement from the committee for autoimmune serology of the International Autoimmune Hepatitis Group. *J Hepatol* 2004; **41**: 677-683 [PMID: 15464251 DOI: 10.1016/j.jhep.2004.08.002]

71   **Vasuri F**, Malvi D, Gruppioni E, Grigioni WF, D'Errico-Grigioni A. Histopathological evaluation of recurrent hepatitis C after liver transplantation: a review. *World J Gastroenterol* 2014; **20**: 2810-2824 [PMID: 24659874 DOI: 10.3748/wjg.v20.i11.2810]

72   **Zen Y**, Fujii T, Harada K, Kawano M, Yamada K, Takahira M, Nakanuma Y. Th2 and regulatory immune reactions are increased in immunoglobin G4-related sclerosing pancreatitis and cholangitis. *Hepatology* 2007; **45**: 1538-1546 [PMID: 17518371 DOI: 10.1002/hep.21697]

73   **Lodato F**, Azzaroli F, Tamè MR, Di Girolamo M, Buonfiglioli F, Mazzella N, Cecinato P, Roda E, Mazzella G. G-CSF in Peg-IFN induced neutropenia in liver transplanted patients with HCV recurrence. *World J Gastroenterol* 2009; **15**: 5449-5454 [PMID: 19916175 DOI: 10.3748/wjg.15.5449]

74   **Aguilera I**, Wichmann I, Sousa JM, Bernardos A, Franco E, Garcia-Lozano R, Gonzalez-Escribano MF, Núñez-Roldán A. Antibodies against glutathione S-transferase T1 in patients with immune hepatitis after liver transplantation. *Transplant Proc* 2003; **35**: 712 [PMID: 12644106 DOI: 10.1016/S0041-1345(03)00059-9]

75   **Aguilera I**, Sousa JM, Gavilán F, Bernardos A, Wichmann I, Nuñez-Roldán A. Glutathione S-transferase T1 mismatch constitutes a risk factor for de novo immune hepatitis after liver transplantation. *Liver Transpl* 2004; **10**: 1166-1172 [PMID: 15350010 DOI: 10.1002/lt.20209]

76   **Aguilera I**, Sousa JM, Gavilan F, Bernardos A, Wichmann I, Nuñez-Roldan A. Glutathione S-transferase T1 genetic mismatch is a risk factor for de novo immune hepatitis in liver transplantation. *Transplant Proc* 2005; **37**: 3968-3969 [PMID: 16386599 DOI: 10.1016/j.transproceed.2005.10.042]

77   **Aguilera I**, Sousa JM, Gavilan F, Gomez L, Alvarez-Márquez A, Núñez-Roldán A. Complement component 4d immunostaining in liver allografts of patients with de novo immune hepatitis. *Liver Transpl* 2011; **17**: 779-788 [PMID: 21425430 DOI: 10.1002/lt.22302]

78   **Aguilera I**, Sousa JM, Praena JM, Gómez-Bravo MA, Núñez-Roldan A. Choice of calcineurin inhibitor may influence the development of de novo immune hepatitis associated with anti-GSTT1 antibodies after liver transplantation. *Clin Transplant* 2011; **25**: 207-212 [PMID: 20236132 DOI: 10.1111/j.1399-0012.2010.01221.x]

79   **Salcedo M**, Rodríguez-Mahou M, Rodríguez-Sainz C, Rincón D, Alvarez E, Vicario JL, Catalina MV, Matilla A, Ripoll C, Clemente G, Bañares R. Risk factors for developing de novo autoimmune hepatitis associated with anti-glutathione S-transferase T1 antibodies after liver transplantation. *Liver Transpl* 2009; **15**: 530-539 [PMID: 19399747 DOI: 10.1002/lt.21721]

80   **Wiesner RH**, Steffen BJ, David KM, Chu AH, Gordon RD, Lake JR. Mycophenolate mofetil use is associated with decreased risk of late acute rejection in adult liver transplant recipients. *Am J Transplant* 2006; **6**: 1609-1616 [PMID: 16827861 DOI: 10.1111/j.1600-6143.2006.01382.x]

81   **McCaughan GW**, Zekry A. Effects of immunosuppression and organ transplantation on the natural history and immuno-pathogenesis of hepatitis C virus infection. *Transpl Infect Dis* 2000; **2**: 166-185 [PMID: 11429029 DOI: 10.1034/j.1399-3062.2000.020403.x]

82   **Zignego AL**, Giannini C, Gragnani L, Piluso A, Fognani E. Hepatitis C virus infection in the immunocompromised host: a complex scenario with variable clinical impact. *J Transl Med* 2012; **10**: 158 [PMID: 22863056 DOI: 10.1186/1479-5876-10-158]

83   **Zignego AL**, Wojcik GL, Cacoub P, Visentini M, Casato M, Mangia A, Latanich R, Charles ED, Gragnani L, Terrier B, Piazzola V, Dustin LB, Khakoo SI, Busch MP, Lauer GM, Kim AY, Alric L, Thomas DL, Duggal P. Genome-wide association study of hepatitis C virus- and cryoglobulin-related vasculitis. *Genes Immun* 2014; **15**: 500-505 [PMID: 25030430 DOI: 10.1038/gene.2014.41]

84   **Manns MP**, Czaja AJ, Gorham JD, Krawitt EL, Mieli-Vergani G, Vergani D, Vierling JM. Diagnosis and management of autoimmune hepatitis. *Hepatology* 2010; **51**: 2193-2213 [PMID: 20513004 DOI: 10.1002/hep.23584]

Baishideng®